ANN ARBOR STAGE III DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for ANN ARBOR STAGE III DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE III DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE III DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test new weapon in fight against aggressive blood cancer
Disease control OngoingThis early-stage study is testing if adding a new drug called parsaclisib to a standard chemotherapy regimen (R-CHOP) is safe and more effective for patients with newly diagnosed, high-risk diffuse large B-cell lymphoma. The main goals are to find the safest dose of the new combi…
Matched conditions: ANN ARBOR STAGE III DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Can adding a pill to standard chemo beat aggressive blood cancer?
Disease control OngoingThis study is testing whether adding the drug lenalidomide to a standard chemotherapy combination works better for treating newly diagnosed aggressive lymphoma. About 350 patients with stage II-IV disease will receive either the standard treatment or the standard treatment plus l…
Matched conditions: ANN ARBOR STAGE III DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
New pill aims to boost cancer fight for seniors
Disease control TerminatedThis study is for people aged 75 and older who have just been diagnosed with certain aggressive types of lymphoma. It compares the current standard treatment (a combination of drugs called R-miniCHOP) to that same treatment plus a new oral drug called CC-486. The main goals are t…
Matched conditions: ANN ARBOR STAGE III DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC